newsfilter
← Latest News
GlobeNewswire·

Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award

  • Mesoblast Limited received the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards on November 19, 2026.
  • The award recognizes Mesoblast's evolution to a commercial-stage biotechnology company following the U.S. FDA approval & launch of Ryoncil (remestemcel-L-rknd).
  • Ryoncil is the first mesenchymal stromal cell therapy approved by the FDA for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months & older.
  • Chief Executive Dr. Silviu Itescu stated the Ryoncil launch established a strong commercial foundation & enabled patient access to a life-changing product.
  • Mesoblast develops allogeneic cellular medicines using proprietary mesenchymal lineage platforms to counter severe inflammation.
  • The company is expanding Ryoncil development for SR-aGvHD in adults & biologic-resistant inflammatory bowel disease.
  • Rexlemestrocel-L is being developed for heart failure & chronic low back pain indications.
  • Mesoblast holds over 1,000 granted patents or applications covering its cell therapies, with commercial protection extending to at least 2044.
  • The company has established commercial partnerships in Japan, Europe, & China.
  • Mesoblast is listed on the Nasdaq (MESO) & Australian Securities Exchange (MSB) with locations in Australia, the U.S., & Singapore.
Company
Mesoblast Limited
Keywords
Australian Stock Exchange:MSB.AX, Mesoblast Limited